Recently, immune checkpoint inhibitor (ICI) plus chemotherapy has shown promising results in treating patients with advanced ERBB2-negative GC/GEJC, making it a new first-line treatment for this subset of patients (Shitara et al., 2020; Janjigian et al., 2021; Akkanapally et al., 2024). Here, ERBB2 is linked to gastric cancer.